A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Official record

Identifier

NCT07518043

Recruiting locations

country

China

Interventions studied

HLX18OPDIVO®

Lead sponsor

Shanghai Henlius Biotech

Target enrolment

174 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Recruiting

First posted

Apr 8, 2026

Last updated on the registry

Jul 27, 2026

Age

18 Years – 70 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Participants must have signed and dated an IRB/IEC approved written informed consent form.
2. Aged 18 to 70 years at the time of signing the ICF.
3. 18 kg/m² ≤ BMI ≤ 30 kg/m² and 50 kg ≤ body weight ≤ 85 kg.
4. Histologically confirmed solid tumors (EC/GEJC, Melanoma, or UC) status post R0 resection.
5. For EC/GEJC: residual pathologic disease (non-pCR) following neoadjuvant chemoradiotherapy and R0 resection.
6. For Melanoma: Stage IIB-IV after complete surgical resection with documented negative margins.
7. For UC: High-risk muscle-invasive urothelial carcinoma (MIUC) following radical resection (R0).
8. Documented disease-free status (no recurrence) by imaging and physical exam within 4 weeks prior to randomization.
9. Adequate recovery from prior surgery or systemic therapy.
10. ECOG Performance Status of 0.
11. Adequate organ function.
12. Agreement to use effective contraception (negative pregnancy test for WOCBP).

Exclusion Criteria:

1. History of illicit drug use or alcohol abuse within 12 months prior to randomization.
2. Tumor-specific exclusions: cervical esophageal cancer, Stage IV EC/GEJC, or ocular melanoma.
3. UC-specific surgical exclusions: status post partial cystectomy or partial nephrectomy.
4. EC/GEJC treatment violations: failure to receive mandatory preoperative concurrent CRT (mono-therapy is ineligible).
5. Prior treatment with nivolumab or any other immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4).
6. Other primary active malignancies within 5 years or history of organ/bone marrow transplantation.
7. Significant cardiovascular disease (MI, cerebrovascular disease) or unstable arrhythmia (QTc \> 450ms/470ms) within 6 months.
8. Chronic heart failure (NYHA Class III-IV) or LVEF \< 50% at screening.
9. Presence of interstitial pneumonia, pneumonitis, or severe lung function abnormalities.
10. Active autoimmune disease requiring systemic immunosuppressive therapy.
11. Known HIV infection, active Hepatitis B/C, or active pulmonary tuberculosis.
12. Peripheral neuropathy ≥ Grade 2 or history of carcinomatosis meningitis.
13. Use of systemic corticosteroids (\>10 mg/day prednisone equivalent), immunosuppressants, or live vaccines within 28 days.
14. Recent or planned participation in other investigational drug, device, or surgical studies.
15. Severe allergic reactions to monoclonal antibodies or any condition deemed unsuitable by the investigator.
16. The investigator has a clear reason to believe that participation in this study would be detrimental to the participant.